Accord Healthcare today announced further expansion in Europe with the opening of a new operation in Basel, Switzerland and further expansion of operations in Austria. These moves follow news of the company’s recent commitment in the UK through the investment of a manufacturing site in Fawden, Newcastle-upon-Tyne.
Already among the largest supplier of medicines in the UK and the most significant provider of chemotherapy in the European Union countries, the company says it will launch “a large pipeline of generics, biosimilars and novel pharmaceuticals over the coming years, with a focus in therapeutic areas such as oncology, critical care, auto-immune and central nervous system conditions”.
Richard Hummel, Accord’s Country Manager, Switzerland, commented: “Switzerland is renowned for its pharmaceutical, biotechnology and science industry that attracts international talent. We plan to bring that talent into the Accord family to help us achieve our global vision to be a major top 5 pan-region generics company by 2021.”
Ewald Sternad, Country Manager, Austria, added: “We are delighted to continue the growth trajectory that we have already achieved in Austria... These investments are a result of doubling market share of our targeted chemotherapy product and the increase of sales emanating from secondary-care prescribers.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.